Eli Lilly partners with ABL Biotech on bispecific antibodies via the Grabody platform in a deal worth up to $2.6B. Read more ...

Novo Nordisk A/S faces intensifying GLP-1 competition, notably from Eli Lilly, prompting price cuts for Wegovy. Learn more ...

The drugmaker’s stock checks all the boxes for a split. the price keeps climbing, the company is on fire, and it’s a bull ...

Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.

South Korea’s newest billionaire is Lee Sang-hoon, founder of ABL Bio, after it struck a $2.6 billion licensing and joint ...

Researchers monitoring the brain activity of a patient with a severe binge-eating problem reported that Eli Lilly's GLP-1 ...

Lilly will also gain certain rights to MeiraGTx’s proprietary riboswitch technology for use in gene editing in the eye. Under ...

Historical trends show that even leading firms can experience abrupt market fluctuations, where stocks can plummet ...

Eli Lilly (LLY) stock is trading at record highs after the pharmaceutical company reached a deal with the White House to ...

Novo Nordisk and Eli Lilly denied weight-loss drug partnership with Mangoceuticals on Thursday, hours after the telehealth ...

Eli Lilly (NYSE:LLY) edged nearly 3% higher on Wednesday after the pharmaceutical giant said it will withdraw from CVS Health ...

Even by dramatically lowering the prices of some of its medications, the drug giant is still outpacing its rivals and nearing ...